Germany had opened applications for a fully funded SLE programme at Humboldt University, offering scholarships and training ...
Group sales were +6% at constant exchange rates (CER)1, -5% when reported in CHF and +9% in USD2, in the first three months, driven by high demand for our innovative medicines and diagnostics.Pharmace ...
Cartesian Therapeutics' lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b. Find ...
The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for obinutuzumab for the treatment of systemic lupus erythematosus (SLE). Findings ...
The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental Biologics License Application for Gazyva® ...
RHHBY's Gazyva gets FDA review for lupus as strong trial data and pipeline wins across neurology and MS bolster growth outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results